New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B ...

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that ...

Sacituzumab tirumotecan demonstrated activity in a phase 2 trial of patients with advanced TNBC who had received no prior treatment in the advanced setting.

Recent advances in cancer research have underscored the critical role of myeloid cells in shaping tumor microenvironments ...

Personalis, Inc. (NASDAQ: PSNL) has unveiled breakthrough clinical data showing its NeXT Personal ctDNA blood test can ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

BMY strikes a billion-dollar deal with BNTX to co-develop BNT327, a bispecific antibody targeting PD-L1 and VEGF-A in solid ...

Agenus announced it signed a partnership agreement with Zydus Lifesciences to expand patient access to Botensilimab and ...

The meeting of the American Society of Oncology focused on optimizing immunotherapy and other advanced treatments for ...